FCRN antagonists and methods of use
US10316073B2 · kind B2 · utility
6Cited by
17References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 23, 2014 |
| Grant date | Jun 11, 2019 |
| Priority date | — |
| Expiry date | Jan 8, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.